These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25012568)

  • 21. Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors.
    Chung SH; Park J; Lee JW; Song J; Jung D; Min KH
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1822-1833. PubMed ID: 32972253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.
    Venkatesan AM; Dehnhardt CM; Chen Z; Santos ED; Dos Santos O; Bursavich M; Gilbert AM; Ellingboe JW; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham R; Mansour TS
    Bioorg Med Chem Lett; 2010 Jan; 20(2):653-6. PubMed ID: 19954970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
    Wang S; Wood G; Meades C; Griffiths G; Midgley C; McNae I; McInnes C; Anderson S; Jackson W; Mezna M; Yuill R; Walkinshaw M; Fischer PM
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4237-40. PubMed ID: 15261277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-based design of PDK1 inhibitors.
    Poulsen A; Blanchard S; Soh CK; Lee C; Williams M; Wang H; Dymock B
    Bioorg Med Chem Lett; 2012 Jan; 22(1):305-7. PubMed ID: 22119465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
    Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity.
    Islam I; Bryant J; Chou YL; Kochanny MJ; Lee W; Phillips GB; Yu H; Adler M; Whitlow M; Ho E; Lentz D; Polokoff MA; Subramanyam B; Wu JM; Zhu D; Feldman RI; Arnaiz DO
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3814-8. PubMed ID: 17531483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability.
    Kawada H; Ebiike H; Tsukazaki M; Yamamoto S; Koyama K; Nakamura M; Morikami K; Yoshinari K; Yoshida M; Ogawa K; Shinma N; Tsukuda T; Ohwada J
    Bioorg Med Chem; 2015 Dec; 23(24):7650-60. PubMed ID: 26613634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
    Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres.
    Gehringer M; Forster M; Pfaffenrot E; Bauer SM; Laufer SA
    ChemMedChem; 2014 Nov; 9(11):2516-27. PubMed ID: 25139757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines.
    Reiersølmoen AC; Aarhus TI; Eckelt S; Nørsett KG; Sundby E; Hoff BH
    Bioorg Chem; 2019 Jul; 88():102918. PubMed ID: 30999245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.
    Coumar MS; Tsai MT; Chu CY; Uang BJ; Lin WH; Chang CY; Chang TY; Leou JS; Teng CH; Wu JS; Fang MY; Chen CH; Hsu JT; Wu SY; Chao YS; Hsieh HP
    ChemMedChem; 2010 Feb; 5(2):255-67. PubMed ID: 20039358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
    Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
    Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological evaluation of 4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-substituted-phenoxy)pyrimidines as dual EGFR/ErbB-2 kinase inhibitors.
    Li S; Guo C; Zhao H; Tang Y; Lan M
    Bioorg Med Chem; 2012 Jan; 20(2):877-85. PubMed ID: 22182581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
    Arcari JT; Beebe JS; Berliner MA; Bernardo V; Boehm M; Borzillo GV; Clark T; Cohen BD; Connell RD; Frost HN; Gordon DA; Hungerford WM; Kakar SM; Kanter A; Keene NF; Knauth EA; Lagreca SD; Lu Y; Martinez-Alsina L; Marx MA; Morris J; Patel NC; Savage D; Soderstrom CI; Thompson C; Tkalcevic G; Tom NJ; Vajdos FF; Valentine JJ; Vincent PW; Wessel MD; Chen JM
    Bioorg Med Chem Lett; 2013 May; 23(10):3059-63. PubMed ID: 23566514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors.
    Dincer S; Cetin KT; Onay-Besikci A; Ölgen S
    J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1080-7. PubMed ID: 22957720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation.
    Egert-Schmidt AM; Dreher J; Dunkel U; Kohfeld S; Preu L; Weber H; Ehlert JE; Mutschler B; Totzke F; Schächtele C; Kubbutat MH; Baumann K; Kunick C
    J Med Chem; 2010 Mar; 53(6):2433-42. PubMed ID: 20170163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Ustilago maydis Aurora kinase as a novel antifungal target.
    Tückmantel S; Greul JN; Janning P; Brockmeyer A; Grütter C; Simard JR; Gutbrod O; Beck ME; Tietjen K; Rauh D; Schreier PH
    ACS Chem Biol; 2011 Sep; 6(9):926-33. PubMed ID: 21671622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors.
    Yang B; Wu Q; Huan X; Wang Y; Sun Y; Yang Y; Liu T; Wang X; Chen L; Xiong B; Zhao D; Miao Z; Chen D
    Bioorg Med Chem Lett; 2021 Feb; 33():127749. PubMed ID: 33340663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and molecular modelling studies of 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors.
    Loidreau Y; Deau E; Marchand P; Nourrisson MR; Logé C; Coadou G; Loaëc N; Meijer L; Besson T
    Eur J Med Chem; 2015 Mar; 92():124-34. PubMed ID: 25549552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6
    Ferguson FM; Liu Y; Harshbarger W; Huang L; Wang J; Deng X; Capuzzi SJ; Muratov EN; Tropsha A; Muthuswamy S; Westover KD; Gray NS
    J Med Chem; 2020 Jul; 63(14):7817-7826. PubMed ID: 32530623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.